Israel - English - Ministry of Health

propharm ltd - bethanechol chloride - tablets - bethanechol chloride 25 mg - bethanechol - myocholine glenwood is indicated in cases of postoperative urinary retention due to atony of the bladder in adults in diseases in which a stimulation of the bladder muscle is needed.

Israel - English - Ministry of Health

astrazeneca (israel) ltd - sodium zirconium cyclosilicate - powder for suspension - sodium zirconium cyclosilicate 10 g/sachet - sodium zirconium cyclosilicate - lokelma is indicated for the treatment of hyperkalaemia in adult patients

Israel - English - Ministry of Health

astrazeneca (israel) ltd - sodium zirconium cyclosilicate - powder for suspension - sodium zirconium cyclosilicate 5 g/sachet - sodium zirconium cyclosilicate - lokelma is indicated for the treatment of hyperkalaemia in adult patients

Israel - English - Ministry of Health

astrazeneca (israel) ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - nasal spray, suspension - b/phuket/3073/2013 (b/yamagata lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/darwin/9/2021 (h3n2)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 7 ±0.5 log10 ffu^a / 0.2 ml - influenza, inactivated, split virus or surface antigen - influenza, purified antigen - flumist quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza a subtype viruses ad type b viruses contained in the vaccine. flumist quadrivalent is approved for use in persons 2 through 49 years of age.

Israel - English - Ministry of Health

astra zeneca (israel) ltd - fulvestrant - solution for injection - fulvestrant 250 mg / 5 ml - fulvestrant - fulvestrant - monotherapy :faslodex is indicated for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women: not previously treated with endocrine therapy, orwith disease relapse on or after adjuvant endocrine therapy; or disease progression on endocrine therapy.combination therapy with palbociclib: faslodex is indicated for the treatment of hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after endocrine therapy

Israel - English - Ministry of Health

astra zeneca (israel) ltd - fulvestrant - solution for injection - fulvestrant 250 mg / 5 ml - fulvestrant - fulvestrant - monotherapy :faslodex is indicated for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women: not previously treated with endocrine therapy, orwith disease relapse on or after adjuvant endocrine therapy; or disease progression on endocrine therapy.combination therapy with palbociclib: faslodex is indicated for the treatment of hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after endocrine therapy

Israel - English - Ministry of Health

astrazeneca (israel) ltd - fulvestrant - solution for injection - fulvestrant 250 mg / 5 ml - fulvestrant - fulvestrant - monotherapyfaslodex is indicated for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:* not previously treated with endocrine therapy,or* with disease relapse on or after adjuvant endocrine therapy;or* with disease progression on endocrine therapy.combination therapy faslodex is indicated for the treatment of:- hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in men and postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy.- hr- positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.

Israel - English - Ministry of Health

tzamal bio-pharma ltd - quetiapine as fumarate - tablets prolonged release - quetiapine as fumarate 50 mg - quetiapine - quetiapine - seroquel xr is indicated for the treatment of schizophrenia .seroquel xr is effective in preventing relapse in stable schizophrenic patients who have been maintained on seroquel xr. seroquel xr is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorder.treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate.seroquel xr is indicated for the treatment of major depressive episodes in bipolar disorder. seroquel xr is indicated for preventing recurrence in bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment as monotherapy or in combination with lithium or sodium valproate. seroquel xr is indicated for add-on treatment of major depressive episods in patients with major depressive disorder (mdd) who have had sub-optimal response to antidepressant monotherapy (see section 5.1 pharmacodynamic properties). prior to initiating treatment, clinicians should consider the safety profile of seroquel xr (see section 4.4 special warnings and precautions for use).

Israel - English - Ministry of Health

tzamal bio-pharma ltd - quetiapine as fumarate - tablets prolonged release - quetiapine as fumarate 200 mg - quetiapine - quetiapine - seroquel xr is indicated for the treatment of schizophrenia .seroquel xr is effective in preventing relapse in stable schizophrenic patients who have been maintained on seroquel xr. seroquel xr is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorder.treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate.seroquel xr is indicated for the treatment of major depressive episodes in bipolar disorder. seroquel xr is indicated for preventing recurrence in bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment as monotherapy or in combination with lithium or sodium valproate. seroquel xr is indicated for add-on treatment of major depressive episods in patients with major depressive disorder (mdd) who have had sub-optimal response to antidepressant monotherapy (see section 5.1 pharmacodynamic properties). prior to initiating treatment, clinicians should consider the safety profile of seroquel xr (see section 4.4 special warnings and precautions for use).

Israel - English - Ministry of Health

tzamal bio-pharma ltd - quetiapine as fumarate - tablets prolonged release - quetiapine as fumarate 300 mg - quetiapine - quetiapine - seroquel xr is indicated for the treatment of schizophrenia .seroquel xr is effective in preventing relapse in stable schizophrenic patients who have been maintained on seroquel xr. seroquel xr is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorder.treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate.seroquel xr is indicated for the treatment of major depressive episodes in bipolar disorder. seroquel xr is indicated for preventing recurrence in bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment as monotherapy or in combination with lithium or sodium valproate. seroquel xr is indicated for add-on treatment of major depressive episods in patients with major depressive disorder (mdd) who have had sub-optimal response to antidepressant monotherapy (see section 5.1 pharmacodynamic properties). prior to initiating treatment, clinicians should consider the safety profile of seroquel xr (see section 4.4 special warnings and precautions for use).